Next report date
Report period
Q1 2024
EPS estimate
1.60EUR
Revenue estimate
529.92 MEUR
8.9EUR
583.65 MEUR
2.21 BEUR
63.49 M
About GENMAB A/S
Sector
CEO
Jan G. J. van de Winkel
Headquarters
Copenhagen
Website
Employees (FY)
2.2 K
Founded
1998
ISIN
DK0010272202
FIGI
BBG000C5CP96
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where GE9 is featured.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange GENMAB AS DK 1 stocks are traded under the ticker GE9.
GENMAB AS DK 1 is going to release the next earnings report on May 2, 2024. Keep track of upcoming events with our Earnings Calendar.
GE9 earnings for the last quarter are 4.32 EUR per share, whereas the estimation was 3.06 EUR resulting in a 41.35% surprise. The estimated earnings for the next quarter are 2.89 EUR per share. See more details about GENMAB AS DK 1 earnings.
GENMAB AS DK 1 revenue for the last quarter amounts to 634.57 M EUR despite the estimated figure of 601.23 M EUR. In the next quarter revenue is expected to reach 618.60 M EUR.
Yes, you can track GENMAB AS DK 1 financials in yearly and quarterly reports right on TradingView.
GE9 net income for the last quarter is 85.83 M EUR, while the quarter before that showed 284.78 M EUR of net income which accounts for −69.86% change. Track more GENMAB AS DK 1 financial stats to get the full picture.
No, GE9 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, GE9 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GENMAB AS DK 1 stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 2.20 K employees. See our rating of the largest employees — is GENMAB AS DK 1 on this list?
We've gathered analysts' opinions on GENMAB AS DK 1 future price: according to them, GE9 price has a max estimate of 459.41 EUR and a min estimate of 248.67 EUR. Read a more detailed GENMAB AS DK 1 forecast: see what analysts think of GENMAB AS DK 1 and suggest that you do with its stocks.